BERMUDA-BUSINESS-DEVELOP
17.10.2019 19:42:06 CEST | Business Wire | Press release
Premier David Burt officially opened the Bermuda Tech Summit yesterday and announced the country would begin accepting 1:1 U.S. dollar-backed digital currencies for the payment of government taxes, fees and services as part of its efforts to ensure Bermuda continues to lead the development of the global fintech industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005802/en/
Throughout the day, more than 300 attendees, a third of whom travelled to Bermuda from overseas, heard from an impressive array of expert speakers who discussed the transformational impact of technology on investment and business models in a wide range of industry sectors relevant to Bermuda. The Bermuda Business Development Agency (BDA) hosted the free-to-attend summit, titled ‘Focused on the Future,’ in partnership with FinTech Bermuda.
“Technology is the future. If you look at five of the six largest companies in the world today, they are technology companies,” said Premier Burt during the opening keynote conversation with Circle CEO Jeremy Allaire. “We know that embracing new technology is necessary for the future growth of our economy, and so, in Bermuda, we are making sure that we are leading the world in facilitating innovation. If existing and new businesses cannot innovate in Bermuda, they will find other jurisdictions to innovate meaning Bermuda will lose out on opportunities. It is essential that Bermuda remains a centre of innovation and continues to improve our competitive advantage in financial services.”
On why he chose Bermuda to operate his business, Jeremy Allaire said: “To build our international business we needed to find a jurisdiction that understood the breadth of digital assets and the scope of what we want to achieve. Bermuda is way ahead than any other country in this regard. As the adoption of digital currencies becomes mainstream, countries like Bermuda who are participating in the innovation stand to benefit and are helping to create a world where the exchange of value is as efficient, free and open as the exchange of information, knowledge and content is today.”
Keynote speaker Terence Mills, CEO of Al.io and a member of the Forbes Technology Council contributing on the topic of artificial intelligence (AI), spoke to a packed room about the future of work, and the challenges and potential of integrating AI into workflows. He gave an engaging presentation on using technology to drive efficiencies with the U.S. healthcare system as an example case.
Other panels highlighted relevant themes such as the increasing demand from customers for connectivity in hospitality, remote working as a future business model in place of an office and thinking inclusively when it comes to building technological infrastructure. It was clear based on discussions throughout the day that realising the grand promise of innovation and new technology requires a collaborative effort and support from both the public and private sectors.
“The tech-savvy and modern business approach that Bermuda is inculcating serves to enhance our appeal in the eyes of the next generation of business leaders, investors and high-net-worths,” said BDA CEO Roland Andy Burrows during his welcome remarks. “Bermuda has long been a domicile of choice for insurance, asset management and trusts amongst many other industries, thanks to the stability, quality and ease of doing business it offers. A combination of these same features, along with our future-focused approach, are now attracting technologists and innovators, the likes of whom are with us today.”
The Bermuda Tech Summit was the capstone event of the inaugural Bermuda Tech Week 2019, which continues tomorrow with Tech Beach Retreat, which is being held in Bermuda for the first time.
Sponsors and partners throughout the week include 24 Exchange, Appleby, Argo Group, Bermuda Economic Development Corporation, Bermuda Tourism Authority, Blockchain Triangle, Blockchain Radio, ChainThat, Circle, Conyers, Google, Gosling’s, Swan Group, The Royal Gazette, Walkers and Xceedance.
Learn more about Bermuda Tech Week 2019 by visiting www.bermudatechweek.bm .
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005802/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
